Donor APCs are required for maximal GVHD but not for GVL

被引:256
作者
Matte, CC
Liu, JL
Cormier, J
Anderson, BE
Athanasiadis, I
Jain, D
McNiff, J
Shlomchik, W
机构
[1] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA
[2] Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA
[3] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA
[4] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA
[5] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA
关键词
D O I
10.1038/nm1089
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Graft-versus-host disease (GVHD) is a major source of morbidity in allogenic stem cell transplantation(1). We previously showed that recipient antigen-presenting cells (APCs) are required for CD8-dependent GVHD in a mouse model across only minor histocompatibility antigens ( minor H antigens)(2). However, these studies did not address the function of donor-derived APCs after GVHD is initiated. Here we show that GVHD develops in recipients of donor major histocompatibility complex class I - deficient (MHC I-) bone marrow. Thus, after initial priming, CD8 cells caused GVHD without a further requirement for hematopoietic APCs, indicating that host APCs are necessary and sufficient for GHVD. Nonetheless, GVHD was less severe in recipients of MHC I- bone marrow. Therefore, once initiated, GVHD is intensified by donor-derived cells, most probably donor APCs cross-priming alloreactive CD8 cells. Nevertheless, donor APCs were not required for CD8-mediated graft-versus-leukemia (GVL) against a mouse model of chronic-phase chronic myelogenous leukemia. These studies identify donor APCs as a new target for treating GVHD, which may preserve GVL.
引用
收藏
页码:987 / 992
页数:6
相关论文
共 31 条
[1]   Memory CD4+ T cells do not induce graft-versus-host disease [J].
Anderson, BE ;
McNiff, J ;
Yan, J ;
Doyle, H ;
Mamula, M ;
Shlomchik, MJ ;
Shlomchik, WD .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) :101-108
[2]   REJECTION OF CLASS-I MHC-DEFICIENT HEMATOPOIETIC-CELLS BY IRRADIATED MHC-MATCHED MICE [J].
BIX, M ;
LIAO, NS ;
ZIJLSTRA, M ;
LORING, J ;
JAENISCH, R ;
RAULET, D .
NATURE, 1991, 349 (6307) :329-331
[3]  
BLAND PW, 1992, IMMUNOLOGY, V75, P366
[4]   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution [J].
Chakrabarti, S ;
Mackinnon, S ;
Chopra, R ;
Kottaridis, PD ;
Peggs, K ;
O'Gorman, P ;
Chakraverty, R ;
Marshall, T ;
Osman, H ;
Mahendra, P ;
Craddock, C ;
Waldmann, H ;
Hale, G ;
Fegan, CD ;
Yong, K ;
Goldstone, AH ;
Linch, DC ;
Milligan, DW .
BLOOD, 2002, 99 (12) :4357-4363
[5]   Functional differences between memory and naive CD8 T cells [J].
Cho, BK ;
Wang, CY ;
Sugawa, S ;
Eisen, HN ;
Chen, JZ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2976-2981
[6]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[7]   A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease [J].
Cragg, L ;
Blazar, BR ;
Defor, T ;
Kolatker, N ;
Miller, W ;
Kersey, J ;
Ramsay, N ;
McGlave, P ;
Filipovich, A ;
Weisdorf, D .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (4A) :441-447
[8]  
CROFT M, 1994, J IMMUNOL, V152, P2675
[9]   INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].
DALEY, GQ ;
VANETTEN, RA ;
BALTIMORE, D .
SCIENCE, 1990, 247 (4944) :824-830
[10]   Acute graft-vs-host disease: Pathobiology and management [J].
Goker, H ;
Haznedaroglu, IC ;
Chao, NJ .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (03) :259-277